Terremoto Biosciences
Terremoto Biosciences is a privately held, clinical-stage biotechnology company based in South San Francisco, California, building a covalent drug discovery and development engine around lysine-based covalency. Founded in 2022 by veterans of Principia Biopharma and backed by OrbiMed and Third Rock Ventures across Series A ($75M), Series B ($175M) and Series C ($108M) financings, the company designs highly selective small-molecule medicines aimed both at improving on known drug targets and at reaching targets previously considered undruggable. Its lead program, TER-2013, is an AKT1-selective inhibitor granted FDA Fast Track designation for breast cancer, with additional work in oncology and hereditary hemorrhagic telangiectasia. Terremoto is a therapeutics developer, not a software vendor: it publishes no public API, developer portal, SDK or machine-readable API contract, and its public web surface is a corporate marketing site covering science, pipeline, news and careers.
Terremoto Biosciences is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Drug Discovery, and Life Sciences.
Terremoto Biosciences’ developer surface includes engineering blog, support, and 6 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 3
The organization behind the API
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.